Targeting B cells to treat systemic lupus erythematosus

Arlene T. Tieng, Gisele Zandman-Goddard, Elena Peeva

Research output: Contribution to journalReview articlepeer-review


B cells play a central role in the pathogenesis of systemic lupus erythematosus. Of late, there has been growing interest in utilizing B cells as targets for the development of new treatments for this frequently devastating disease. In addition to producing (auto)antibodies, B cells are involved in a variety of autoantibody-independent pathogenic mechanisms, such as effector functions, cytokine production and costimulation. Therefore, depleting B cells or inhibiting their actions can suppress the immune hyperactivity that is characteristic of systemic lupus erythematosus. This article examines the latest advances in novel B-cell-directed therapies for patients with systemic lupus erythematosus.

Original languageEnglish
Pages (from-to)627-636
Number of pages10
JournalInternational Journal of Clinical Rheumatology
Issue number6
StatePublished - Dec 2010
Externally publishedYes


  • B-cell depletion
  • B-cell-directed therapies
  • B-lymphocyte stimulator
  • CD20
  • CD22
  • costimulation
  • systemic lupus erythematosus


Dive into the research topics of 'Targeting B cells to treat systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this